Citius Pharmaceuticals, Inc. (CTXR)

Market Cap	30.96M
Revenue (ttm)	n/a
Net Income (ttm)	-40.99M
Shares Out	17.01M
EPS (ttm)	-4.78
PE Ratio	n/a
Forward PE	2.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	828,886
Open	1.800
Previous Close	1.720
Day's Range	1.665 - 1.810
52-Week Range	0.650 - 12.837
Beta	1.41
Analysts	Strong Buy
Price Target	53.00 (+2,812.09%)
Earnings Date	Aug 12, 2025

About CTXR

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial fo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 23
• Stock Exchange: NASDAQ
• Ticker Symbol: CTXR
• Website: https://citiuspharma.com

Analyst Summary

According to 3 analysts, the average rating for CTXR stock is "Strong Buy." The 12-month stock price target is $53.0, which is an increase of 2,812.09% from the latest price.

Price Target

$53.0

(2,812.09% upside)

Analyst Consensus: Strong Buy